Trial Profile
Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jul 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Aortitis; Pancreatitis; Retroperitoneal fibrosis; Sialadenitis; Thyroiditis
- Focus Biomarker; Therapeutic Use
- 07 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 31 Jul 2014 New trial record